Beam Therapeutics Inc. (BEAM) is a Healthcare stock trading at $34.12 (as of 2026-06-18), with a market capitalization of $3.04B and a trailing P/E of -60.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Beam Therapeutics Inc. is developing precision genetic medicines and related therapies for patients in the United States, with programs that include candidates for sickle cell disease, beta thalassemia, relapsed/refractory T-cell acute lymphoblastic leukemia, and liver and other disorders such as Glycogen Storage Disease Type Ia and alpha-1 antitrypsin deficiency.